ENDOCYTE INC Marketing Agreements

30 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
Obtain marketing approval of our phase 3-ready SMDC, EC145, for use in women with platinum-resistant ovarian cancer. We plan to initiate a randomized, controlled, double-blinded...
Marketing Agreements
ENDOCYTE INC
IN
2011
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2011
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2011
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
MD
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
MD
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
NY
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
IN
2010
obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer
Marketing Agreements
ENDOCYTE INC
DE
2010